Phase Genomics
United States
- Seattle, Washington
- 06/03/2024
- Unknown
- $1,500,000
Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software.
Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.
- Industry Biotechnology Research
- Website https://phasegenomics.com/
- LinkedIn https://www.linkedin.com/company/phase-genomics-inc/
Related People
Ivan Liachko 🇺🇦Co Founder
United States -
Seattle, Washington
A molecular geneticist/genomicist with over two decades of experience in wet-lab and computational biology. Founder and CEO of Seattle-based Phase Genomics Inc. (est. 2015). Passionate about applying genomic technology to improve our world and mentoring scientists interested in commercialization.
**Citations on Google Scholar*: https://scholar.google.com/citations?user=VBQJ1-gAAAAJ&hl=en
**Other Publications & News*: https://phasegenomics.com/publications/
Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
KOSMOS | $5,000,000 | (Jun 3, 2026)
Phosio Corporation | $4,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Contraline | $92,500,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Westmag | $11,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)